These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32678144)

  • 41. Isolation and light chain shuffling of a Plasmodium falciparum AMA1-specific human monoclonal antibody with growth inhibitory activity.
    Seidel-Greven M; Addai-Mensah O; Spiegel H; Chiegoua Dipah GN; Schmitz S; Breuer G; Frempong M; Reimann A; Klockenbring T; Fischer R; Barth S; Fendel R
    Malar J; 2021 Jan; 20(1):37. PubMed ID: 33430886
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01.
    Payne RO; Milne KH; Elias SC; Edwards NJ; Douglas AD; Brown RE; Silk SE; Biswas S; Miura K; Roberts R; Rampling TW; Venkatraman N; Hodgson SH; Labbé GM; Halstead FD; Poulton ID; Nugent FL; de Graaf H; Sukhtankar P; Williams NC; Ockenhouse CF; Kathcart AK; Qabar AN; Waters NC; Soisson LA; Birkett AJ; Cooke GS; Faust SN; Woods C; Ivinson K; McCarthy JS; Diggs CL; Vekemans J; Long CA; Hill AV; Lawrie AM; Dutta S; Draper SJ
    J Infect Dis; 2016 Jun; 213(11):1743-51. PubMed ID: 26908756
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunized.
    Miura K; Zhou H; Muratova OV; Orcutt AC; Giersing B; Miller LH; Long CA
    Infect Immun; 2007 Dec; 75(12):5827-36. PubMed ID: 17923516
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of a potent combination of key Plasmodium falciparum merozoite antigens that elicit strain-transcending parasite-neutralizing antibodies.
    Pandey AK; Reddy KS; Sahar T; Gupta S; Singh H; Reddy EJ; Asad M; Siddiqui FA; Gupta P; Singh B; More KR; Mohmmed A; Chitnis CE; Chauhan VS; Gaur D
    Infect Immun; 2013 Feb; 81(2):441-51. PubMed ID: 23184525
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1.
    Dutta S; Dlugosz LS; Drew DR; Ge X; Ababacar D; Rovira YI; Moch JK; Shi M; Long CA; Foley M; Beeson JG; Anders RF; Miura K; Haynes JD; Batchelor AH
    PLoS Pathog; 2013; 9(12):e1003840. PubMed ID: 24385910
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys.
    Pichyangkul S; Tongtawe P; Kum-Arb U; Yongvanitchit K; Gettayacamin M; Hollingdale MR; Limsalakpetch A; Stewart VA; Lanar DE; Dutta S; Angov E; Ware LA; Bergmann-Leitner ES; House B; Voss G; Dubois MC; Cohen JD; Fukuda MM; Heppner DG; Miller RS
    Vaccine; 2009 Dec; 28(2):452-62. PubMed ID: 19857448
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults.
    Sklar MJ; Maiolatesi S; Patterson N; Sedegah M; Limbach K; Teneza-Mora N; Chuang I; Hollis-Perry KM; Banania JG; Guzman I; Ganeshan H; Reyes S; Hollingdale MR; Wong M; Lindstrom A; Reyes A; Alcorta Y; Garver L; Bankard K; Belmonte A; Belmonte M; Huang J; Gowda K; Inoue S; Velasco R; Bergmann-Leitner E; Hutter J; Lee T; Adams N; Chaudhury S; Hunt D; Tamminga C; Berrie E; Bellamy D; Bittaye M; Ewer K; Diggs C; Soisson LA; Lawrie A; Hill A; Richie TL; Villasante E; Epstein JE; Duplessis CA
    PLoS One; 2021; 16(9):e0256980. PubMed ID: 34495988
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection.
    Tamminga C; Sedegah M; Maiolatesi S; Fedders C; Reyes S; Reyes A; Vasquez C; Alcorta Y; Chuang I; Spring M; Kavanaugh M; Ganeshan H; Huang J; Belmonte M; Abot E; Belmonte A; Banania J; Farooq F; Murphy J; Komisar J; Richie NO; Bennett J; Limbach K; Patterson NB; Bruder JT; Shi M; Miller E; Dutta S; Diggs C; Soisson LA; Hollingdale MR; Epstein JE; Richie TL
    Hum Vaccin Immunother; 2013 Oct; 9(10):2165-77. PubMed ID: 23899517
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Heterotypic interactions drive antibody synergy against a malaria vaccine candidate.
    Ragotte RJ; Pulido D; Lias AM; Quinkert D; Alanine DGW; Jamwal A; Davies H; Nacer A; Lowe ED; Grime GW; Illingworth JJ; Donat RF; Garman EF; Bowyer PW; Higgins MK; Draper SJ
    Nat Commun; 2022 Feb; 13(1):933. PubMed ID: 35177602
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PfRON3 is an erythrocyte-binding protein and a potential blood-stage vaccine candidate antigen.
    Zhao X; Chang Z; Tu Z; Yu S; Wei X; Zhou J; Lu H; Jiang N; Chen Q
    Malar J; 2014 Dec; 13():490. PubMed ID: 25495792
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antibody levels to multiple malaria vaccine candidate antigens in relation to clinical malaria episodes in children in the Kasena-Nankana district of Northern Ghana.
    Dodoo D; Atuguba F; Bosomprah S; Ansah NA; Ansah P; Lamptey H; Egyir B; Oduro AR; Gyan B; Hodgson A; Koram KA
    Malar J; 2011 May; 10():108. PubMed ID: 21529376
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies.
    King LDW; Pulido D; Barrett JR; Davies H; Quinkert D; Lias AM; Silk SE; Pattinson DJ; Diouf A; Williams BG; McHugh K; Rodrigues A; Rigby CA; Strazza V; Suurbaar J; Rees-Spear C; Dabbs RA; Ishizuka AS; Zhou Y; Gupta G; Jin J; Li Y; Carnrot C; Minassian AM; Campeotto I; Fleishman SJ; Noe AR; MacGill RS; King CR; Birkett AJ; Soisson LA; Long CA; Miura K; Ashfield R; Skinner K; Howarth MR; Biswas S; Draper SJ
    Cell Rep Med; 2024 Jul; 5(7):101654. PubMed ID: 39019011
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preclinical efficacy and immunogenicity assessment to show that a chimeric Plasmodium falciparum UB05-09 antigen could be a malaria vaccine candidate.
    Dinga JN; Gamua SD; Ghogomu SM; Titanji VPK
    Parasite Immunol; 2018 Mar; 40(3):. PubMed ID: 29284177
    [TBL] [Abstract][Full Text] [Related]  

  • 54. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.
    Chuang I; Sedegah M; Cicatelli S; Spring M; Polhemus M; Tamminga C; Patterson N; Guerrero M; Bennett JW; McGrath S; Ganeshan H; Belmonte M; Farooq F; Abot E; Banania JG; Huang J; Newcomer R; Rein L; Litilit D; Richie NO; Wood C; Murphy J; Sauerwein R; Hermsen CC; McCoy AJ; Kamau E; Cummings J; Komisar J; Sutamihardja A; Shi M; Epstein JE; Maiolatesi S; Tosh D; Limbach K; Angov E; Bergmann-Leitner E; Bruder JT; Doolan DL; King CR; Carucci D; Dutta S; Soisson L; Diggs C; Hollingdale MR; Ockenhouse CF; Richie TL
    PLoS One; 2013; 8(2):e55571. PubMed ID: 23457473
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The most polymorphic residue on Plasmodium falciparum apical membrane antigen 1 determines binding of an invasion-inhibitory antibody.
    Coley AM; Parisi K; Masciantonio R; Hoeck J; Casey JL; Murphy VJ; Harris KS; Batchelor AH; Anders RF; Foley M
    Infect Immun; 2006 May; 74(5):2628-36. PubMed ID: 16622199
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diversity covering AMA1-MSP119 fusion proteins as malaria vaccines.
    Faber BW; Younis S; Remarque EJ; Rodriguez Garcia R; Riasat V; Walraven V; van der Werff N; van der Eijk M; Cavanagh DR; Holder AA; Thomas AW; Kocken CH
    Infect Immun; 2013 May; 81(5):1479-90. PubMed ID: 23429538
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity.
    Kusi KA; Faber BW; Thomas AW; Remarque EJ
    PLoS One; 2009 Dec; 4(12):e8110. PubMed ID: 19956619
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synergistic malaria vaccine combinations identified by systematic antigen screening.
    Bustamante LY; Powell GT; Lin YC; Macklin MD; Cross N; Kemp A; Cawkill P; Sanderson T; Crosnier C; Muller-Sienerth N; Doumbo OK; Traore B; Crompton PD; Cicuta P; Tran TM; Wright GJ; Rayner JC
    Proc Natl Acad Sci U S A; 2017 Nov; 114(45):12045-12050. PubMed ID: 29078270
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enhancing neutralization of Plasmodium falciparum using a novel monoclonal antibody against the rhoptry-associated membrane antigen.
    Knudsen AS; Walker MR; Agullet JP; Björnsson KH; Bassi MR; Barfod L
    Sci Rep; 2022 Feb; 12(1):3040. PubMed ID: 35197516
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Strain-specific Plasmodium falciparum growth inhibition among Malian children immunized with a blood-stage malaria vaccine.
    Laurens MB; Kouriba B; Bergmann-Leitner E; Angov E; Coulibaly D; Diarra I; Daou M; Niangaly A; Blackwelder WC; Wu Y; Cohen J; Ballou WR; Vekemans J; Lanar DE; Dutta S; Diggs C; Soisson L; Heppner DG; Doumbo OK; Plowe CV; Thera MA
    PLoS One; 2017; 12(3):e0173294. PubMed ID: 28282396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.